Woman and Man
- | Country :
- France
- Canada
- Italy
- The 2 others...
- | organs : -
- | Specialty : -
Extract
This open-label, parallel group study will evaluate the pharmacokinetics and safety of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer and normal or reduced hepatic function. Patients will receive trastuzumab emtansine intravenously on Day 1 of each 3-week cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Inclusion criteria
- Breast Cancer